MANE Veradermicsdata gap · 11% coveragelimited data
Health Care · Pharmaceutical Preparations · close $108.82 (2026-10-16) · latest quarter in EDGAR:
Veradermics (MANE) has a ThetaGrade House Rating of 68/100 (grade B), ranking #99 of 150 in Health Care. Only 2 pillars have usable data (balance sheet 100, cash flow 19). Data gap: 12 factors without usable data, so 11% of the method weight is covered. TTM revenue growth is — and operating margin —.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, Revenue growth YoY (TTM), EPS growth YoY (TTM), Revenue acceleration, Operating margin, 4Q gross-margin change, Net debt / EBITDA, Interest coverage, FCF margin, P/E (inverted), EV/Sales (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 11% of the full method weight is backed by data.
- Revenue: no standard revenue tag - data gap
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% · no data · —| Revenue growth YoY (TTM) (0.0%)data gap | — | — |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (0.0%)data gap | — | — |
Profitability
weight 18.5% · no data · —| Operating margin (0.0%)data gap | — | — |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→60.0%) · 100| Net debt / EBITDA (0.0%)data gap | — | — |
| Current ratio (60.0%) | 70.53 | 100 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→40.0%) · 19| FCF margin (0.0%)data gap | — | — |
| FCF yield (40.0%) | -1.6% | 19 |
Valuation
weight 12.33% · no data · —| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (0.0%)data gap | — | — |
Technicals (EOD)
| RSI(14) | 45.4 |
| EMA 9 / 21 | 115.78 / 114.78 |
| SMA(177) — 200-day proxy | 91.41 |
| Volume vs 20d avg | 0.70× |
| 20-day return | 0.1% |
Exit-rule monitor
- EXITBalance-sheet stress: negative free cash flow (latest FY)
Data source per metric (SEC XBRL tag or derivation): Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like MANE's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is MANE's House Rating?
- MANE scores 68 out of 100 (grade B) as of 2026-10-16, ranking #99 of 150 Health Care stocks we cover.
- What do analysts say about MANE?
- We do not have enough analyst-sentiment data to score this stock.
- When does MANE report earnings next?
- We could not estimate MANE's next earnings date from SEC filings. Check the company's investor-relations page.
- Is MANE a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology